

Anat Stemmer-Rachamimov

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9022679/publications.pdf>

Version: 2024-02-01

51
papers

4,872
citations

361413

20
h-index

254184

43
g-index

54
all docs

54
docs citations

54
times ranked

10349
citing authors

#	ARTICLE	IF	CITATIONS
1	The AAV9 Variant Capsid AAV-F Mediates Widespread Transgene Expression in Nonhuman Primate Spinal Cord After Intrathecal Administration. <i>Human Gene Therapy</i> , 2022, 33, 61-75.	2.7	16
2	Abstract 2287: Dissecting the heterogeneity of central nervous system hemangioblastomas by single-cell and single-nuclei RNA sequencing. <i>Cancer Research</i> , 2022, 82, 2287-2287.	0.9	0
3	Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. <i>Acta Neuropathologica</i> , 2021, 141, 101-116.	7.7	26
4	A case of antisynthetase syndrome with thrombotic thrombocytopenic purpura. <i>Rheumatology</i> , 2021, 60, e143-e145.	1.9	2
5	Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin. <i>Science Advances</i> , 2021, 7, .	10.3	17
6	Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. <i>Genetics in Medicine</i> , 2021, 23, 1506-1513.	2.4	290
7	Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2024-2024.	1.6	4
8	Mosaicism for Receptor Tyrosine Kinase Activation in a Glioblastoma Involving Both PDGFRA Amplification and NTRK2 Fusion. <i>Oncologist</i> , 2021, 26, 919-924.	3.7	6
9	Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research. <i>Neurology</i> , 2021, 97, S42-S49.	1.1	2
10	Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	21
11	CTNI-54. A SINGLE ARM PHASE II STUDY OF THE DUAL MTORC1/MTORC2 INHIBITOR VISTUSERIB PROVIDED FOR SPORADIC PATIENTS WITH GRADE II-III MENINGIOMAS THAT RECUR OR PROGRESS AFTER SURGERY AND RADIATION. <i>Neuro-Oncology</i> , 2021, 23, vi72-vi72.	1.2	0
12	An update on the CNS manifestations of neurofibromatosis type 2. <i>Acta Neuropathologica</i> , 2020, 139, 643-665.	7.7	102
13	Assessing interobserver variability and accuracy in the histological diagnosis and classification of cutaneous neurofibromas. <i>Neuro-Oncology Advances</i> , 2020, 2, i117-i123.	0.7	3
14	Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 221.	5.2	26
15	EPCO-04. GENOMIC AND EPIGENOMIC HALLMARKS OF SCHWANNOMATOSIS SCHWANNOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii69-ii70.	1.2	0
16	NLRP3 inflammasome activation in human vestibular schwannoma: Implications for tumor-induced hearing loss. <i>Hearing Research</i> , 2019, 381, 107770.	2.0	33
17	Single-cell transcriptomic atlas of the human retina identifies cell types associated with age-related macular degeneration. <i>Nature Communications</i> , 2019, 10, 4902.	12.8	203
18	Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 15, 18-26.	4.1	17

#	ARTICLE	IF	CITATIONS
19	Gene therapy with apoptosis-associated speck-like protein, a newly described schwannoma tumor suppressor, inhibits schwannoma growth in vivo. <i>Neuro-Oncology</i> , 2019, 21, 854-866.	1.2	18
20	TMOD-23. PRECLINICAL DRUG EVALUATION IN A GENETICALLY ENGINEERED MINIPIG MODEL OF NEUROFIBROMATOSIS TYPE 1. <i>Neuro-Oncology</i> , 2019, 21, vi267-vi267.	1.2	0
21	Vestibular Traumatic Neuroma Following Temporal Bone Fracture. <i>Otology and Neurotology</i> , 2019, 40, e62-e65.	1.3	1
22	A proteasome-resistant fragment of NIK mediates oncogenic NF- κ B signaling in schwannomas. <i>Human Molecular Genetics</i> , 2019, 28, 572-583.	2.9	5
23	Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E2077-E2084.	7.1	32
24	Anti-VEGF treatment improves neurological function in tumors of the nervous system. <i>Experimental Neurology</i> , 2018, 299, 326-333.	4.1	14
25	PATH-08. THE IVY GLIOBLASTOMA PATIENT ATLAS - A NOVEL CLINICAL AND RADIO-GENOMICS RESOURCE FOR EARLY PHASE CLINICAL TRIAL DESIGN AND INTERPRETATION. <i>Neuro-Oncology</i> , 2018, 20, vi159-vi159.	1.2	0
26	ACTR-36. A SINGLE ARM PHASE 2 STUDY OF THE DUAL mTORC1/mTORC2 INHIBITOR VISTUSERTIB PROVIDED ON AN INTERMITTENT SCHEDULE FOR NEUROFIBROMATOSIS 2 PATIENTS WITH PROGRESSIVE OR SYMPTOMATIC MENINGIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi19-vi19.	1.2	1
27	GENE-08. SCHWANNOMATOSIS SCHWANNOMAS HARBOR DISTINCT DNA METHYLATION PROFILES. <i>Neuro-Oncology</i> , 2018, 20, vi104-vi104.	1.2	0
28	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018, 175, 998-1013.e20.	28.9	1,260
29	Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings. <i>Human Mutation</i> , 2018, 39, 1112-1125.	2.5	34
30	EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. <i>Neuro-Oncology</i> , 2018, 20, 1185-1196.	1.2	22
31	Genomic landscape of high-grade meningiomas. <i>Npj Genomic Medicine</i> , 2017, 2, .	3.8	130
32	Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1: a consensus overview. <i>Human Pathology</i> , 2017, 67, 1-10.	2.0	275
33	Absence of Alzheimer Disease Neuropathologic Changes in Eyes of Subjects With Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 376-383.	1.7	50
34	Resistance to checkpoint blockade therapy through inactivation of antigen presentation. <i>Nature Communications</i> , 2017, 8, 1136.	12.8	686
35	Sporadic NF2 Mosaic: Multiple spinal schwannomas presenting with severe, intractable pain following pregnancy. <i>Interdisciplinary Neurosurgery: Advanced Techniques and Case Management</i> , 2017, 10, 142-145.	0.3	0
36	YAP Mediates Tumorigenesis in Neurofibromatosis Type 2 by Promoting Cell Survival and Proliferation through a COX-2/EGFR Signaling Axis. <i>Cancer Research</i> , 2016, 76, 3507-3519.	0.9	44

#	ARTICLE	IF	CITATIONS
37	A new patient-derived orthotopic malignant meningioma model treated with oncolytic herpes simplex virus. <i>Neuro-Oncology</i> , 2016, 18, 1278-1287.	1.2	25
38	Directly visualized glioblastoma-derived extracellular vesicles transfer RNA to microglia/macrophages in the brain. <i>Neuro-Oncology</i> , 2016, 18, 58-69.	1.2	245
39	Survival benefit and phenotypic improvement by hamartin gene therapy in a tuberous sclerosis mouse brain model. <i>Neurobiology of Disease</i> , 2015, 82, 22-31.	4.4	14
40	Remote acute demyelination after focal proton radiation therapy for optic nerve meningioma. <i>Journal of Clinical Neuroscience</i> , 2015, 22, 1367-1369.	1.5	4
41	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177.	9.4	821
42	Rapid Intraoperative Molecular Characterization of Glioma. <i>JAMA Oncology</i> , 2015, 1, 662.	7.1	68
43	A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. <i>Oncotarget</i> , 2015, 6, 16981-16997.	1.8	46
44	Kinome Screen Reveals SGK1 as a Therapeutic Target for NF2: Inhibition of mTORC1/2 is More Effective than Rapamycin. <i>FASEB Journal</i> , 2015, 29, 889.4.	0.5	0
45	Stochastic Model of Tsc1 Lesions in Mouse Brain. <i>PLoS ONE</i> , 2013, 8, e64224.	2.5	16
46	Expression of SMARCB1 (INI1) mutations in familial schwannomatosis. <i>Human Molecular Genetics</i> , 2012, 21, 5239-5245.	2.9	51
47	Clinical Features of Schwannomatosis: A Retrospective Analysis of 87 Patients. <i>Oncologist</i> , 2012, 17, 1317-1322.	3.7	171
48	Effect of antiangiogenic therapy on tumor-associated macrophages in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2010-2010.	1.6	1
49	Neurofibromatoses. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 111-111.	1.7	0
50	Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas. <i>FASEB Journal</i> , 2008, 22, 706.8.	0.5	0
51	Sacroccygeal chordomas in patients with tuberous sclerosis complex show somatic loss of <i>TSC1</i> or <i>TSC2</i> . <i>Genes Chromosomes and Cancer</i> , 2004, 41, 80-85.	2.8	60